Cosmos Health Inc. has announced a strategy focused on expanding its vertically integrated platform across pharmaceuticals, nutraceuticals, and over-the-counter products. The company plans to scale its healthcare services component to support ongoing engagement and repeat interaction. As part of its U.S. market expansion, Cosmos Health is establishing domestic manufacturing capacity through an agreement with DolCas Biotech, aiming to produce products locally to mitigate tariff risks and strengthen supply chain resilience. The company’s approach emphasizes building long-term infrastructure and operational durability, with management increasing insider ownership as part of its overall planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1120988) on December 24, 2025, and is solely responsible for the information contained therein.